Insecticides India Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/3hqg7uiu7dmrekajyhve13v3.pdf

Key Takeaways


The Sales Returns Shock

Rajesh Aggarwal: "This year is a muted year in particularly in the H2. It should not be taken as our continued performance. Our performance will be resilient and the results will be visible in the next quarter."

Margin Walk & Profitability

Rajesh Aggarwal: "We want to clearly state, this is not a structural margin erosion. The current phase is driven by market conditions, product mix, tactical business decisions."

The Specialty Pivot & Product Engine

Rajesh Aggarwal: "When I'm saying this, I'm not reducing the value of the generics. I am increasing the value of the specialty. So I'm keeping the same number of generics intact and I am increasing the value of the specialty. So the entire growth in the vision of the company has to come from the specialty."

Raw Material & Pricing Dynamics

Rajesh Aggarwal: "I can vouch almost 2 decades. So more than 2 decades, the prices for many products are the lowest. So chances of further decline from here is very minimal."

Manufacturing Capacity & Capex


International Business & Exports


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthReturn to 8–10% sustainable growthNext 2–3 years
Revenue growthExpect around 10% growthNext 2–3 years
Revenue growth"Should start seeing the growth" with new products and tractionFrom Q1 FY27
EBITDA marginLand full year with double-digit margins (currently 11.8%)FY26
Profitability improvementRationalize business, freeze non-essential capex, improve working capitalOngoing
ROCE/ROEIncrease by 6–7%Over three years
New product launchesAt least 5 launches, including one 9(3) product and 2 exclusivesQ1 FY27
Maharatna launchesAt least 3 launches; one expected in Focus Maharatna rangeFY27
Monocil replacement5–6 new launches to replace INR75 crore productComing season
Dahej plantOperational, improving performanceEnd of FY26 / FY27
Sotanala formulationStart operationsQ1 FY27
Sotanala technical plantStart operations2027
ICS Plots investmentAt least double the investmentFuture (undated)
Freshness Index disclosurePublish for the full year and continue the practiceFY26 full year

Key Metrics

MetricQ3 FY26
Revenue growth8% YoY, volume-led growth
9M revenue₹1,714 cr, up ~4% from ₹1,641 cr in 9M FY25
9M gross profit₹546 cr, up ~7% from ₹509 cr in 9M FY25
9M EBITDA₹201 cr, flattish YoY
9M PAT₹128 cr, flattish YoY
9M EBITDA margin11.8%, down from above 12% earlier in the year
B2C volume growth~3% to 4% in Q3
B2B volume growth~15% in Q3
9M segment mixB2C 76%, B2B 20%, exports 4%
B2C premium product share59% of B2C portfolio in 9M FY26
Sales returns₹50 cr in Q3, total ~₹200 cr for the year, doubled from last year
Kaeros sales~₹89 cr in 9M, ₹15–20 cr in Q3
New product launches5 launched in 9M FY26, at least 5 more planned for Q1 FY27
International registrations180-plus registrations across 22 countries
Bank borrowings utilized~₹200 cr this year, company was zero-debt for prior 2 years